3-(3-methyl-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione

Catalog No. :
ACASGR922
CAS No. :
-
Molecular Formula :
C18H16F3N5O3
Molecular Weight :
407.35

IUPAC Name:3-(3-methyl-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione

3-(3-methyl-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$358.00Login to see priceIn stockInquiry
250mg95%$715.00Login to see priceIn stockInquiry
1g95%$1673.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(3-methyl-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione
IUPAC Name3-(3-methyl-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione
Molecular FormulaC18H16F3N5O3
Molecular Weight407.35
SMILESCN1C=C(C2=CC=C3C(=C2)N(C)C(=O)N3C2CCC(=O)NC2=O)C(C(F)(F)F)=N1
InChI KeyMFVBJZUAWYEZNY-UHFFFAOYSA-N

Synthetic Route by SureRoute

1. ACASGR922 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOKW814 route compound structure diagram
    ACTOKW8142655649-30-0 In Stock
  2. Plus
  3. ACMJZX389 route compound structure diagram
    ACMJZX389497832-99-2 In Stock
  4. Then
  5. ACASGR922 route product structure diagram
    ACASGR922- In Stock
Inquiry

2. ACASGR922 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACIJSZ789 route compound structure diagram
    ACIJSZ7892300099-98-1 In Stock
  2. Plus
  3. ACUPLM825 route compound structure diagram
    ACUPLM8251218790-53-4 In Stock
  4. Then
  5. ACASGR922 route product structure diagram
    ACASGR922- In Stock
Inquiry

Comments (0)